??????????????? ????????? ????????? ?????? ??? ????????????

??????????????? ????????? ???????????? ???????????? ?????? ?????????????????? ??????????????? ?????? ???????????? ??????. ??? ??????????????? ??????????????? ??? ?????? ????????? ???????????? ????????? ??????????????? ????????? ???????????????. ?????? ??????????????? ????????? ??? ?????? ????????? ???????????????, ??? ?????? ????????? diethylnitrosamine (DEN)??? C3H/HeN ?????? ?????? ?????? ???????????? ??? ?????? ????????? ????????? ???????????????. DEN?????? ????????? ???????????? ?????? alkaline phosphatase (ALP) ??????, TUNEL positive ???????????? ??????, ??? ???????????? ?????? ???????????? duct??? ??????, ?????????????????? ????????????, Masson???s trichrome ???????????? ????????? ???????????? ???, ?????? ?????? ?????? ??? ????????? ????????? ???????????? ?????? ???????????? ?????? ?????? ????????? ??? ?????????. ?????????, ??????????????? ?????? ???????????? ????????? ?????? ?????????????????? ??????, ?????? ?????? ??? ????????? ???????????? ??????????????? ???????????? ???????????? ???????????? ?????? ?????? ????????? ??? ?????????. ???????????? ???????????? ????????? ???????????? ??????, ???????????? ???????????? ???????????? ?????? ????????? ???, solvent partition ????????? ???????????? ????????? ???????????? hexane, ethyl acetate, water ???????????? ???????????????. ?????? ??????????????? ?????? ????????? ??????????????? ??????????????? ???, ethyl acetate ???????????? ??????????????? ????????? ?????????????????? ??????????????? ?????? ??????????????? ???????????? ????????? ????????? ????????? ??? ?????????. ????????? ethyl acetate???????????? ???????????? ????????? ????????? ??? ?????????, ??????????????? ????????? ??? ?????? ????????? ????????? ?????????. ???????????????, ??????????????? ????????? ????????????????????? ?????? ????????? ??? ?????? ????????? ???????????? ?????? ??????????????? ????????? ??? ?????? ????????? ????????? ????????? ?????? ???????????????. ?????????, ?????? ??????????????? ?????? ???????????? ?????? ??? ?????? ?????? ???????????? ??????????????? ?????? ????????? ????????? ??? ?????? ????????? ???????????? ??????.clos

Surgical ciliated cyst of the mandible after orthognathic surgery: a case report with review of the literature

Background : Surgical ciliated cysts, also known as postoperative maxillary cysts or implantation cysts, occur mainly in the posterior maxilla after radical maxillary sinus surgery; they rarely develop in the mandible. They are thought to occur when the sinonasal epithelium is infiltrated by a surgical instrument during surgery or as a result of transplantation of bone or cartilage with respiratory epithelium attached. Case presentation : We report a case in which a surgical ciliated cyst developed in the anterior part of the mandible, presumably as a result of bimaxillary orthognathic surgery and genioplasty performed 24 years earlier. We then review the few similar cases reported in the literature. Conclusion : Surgical ciliated cysts in the mandible are extremely rare, but they could occur after simultaneous surgery on the maxilla and mandible, even decades later. To prevent surgical ciliated cysts in the mandible, we recommend that the surgical instruments, especially the saw blade used during bimaxillary surgery, be new or cleaned and that previously placed plates and screws be removed at an appropriate time

Improvements in pulp properties by alkali preextraction and subsequent kraft pulping with controlling H-factor and alkali charge

The objective of this study was to determine the processing conditions for obtaining improved pulp properties from the kraft pulping process with an alkali pre-extraction stage. Before the kraft pulping, a pre-extraction of hemicelluloses from mixed hardwood chips was performed with two different alkali concentrations (3% and 12% as Na2O) at 150 °C for 90 minutes. The kraft pulping of the pre-extracted chips was then conducted in two ways: with either the H-factor alone controlled or with both the H-factor and the alkali charge controlled. When the chips were pre-extracted with the 3% alkali charge and with the kraft pulping controlled to an H-factor of 500, the yield and properties of the pulp were higher than those of the reference kraft pulp. The 12% alkali pre-extraction and kraft pulping resulted in a low yield of screened pulp. However, when the alkali charge and the H-factor were adjusted together, the pulp yield remained constant and the pulp properties improved in comparison to the reference pulp for both the 3 and 12% cases

Role of interleukin-10 in endochondral bone formation in mice: Anabolic effect via the bone morphogenetic protein/Smad pathway

Objective: Interleukin-10 (IL-10) is a pleiotropic immunoregulatory cytokine with a chondroprotective effect that is elevated in cartilage and synovium in patients with osteoarthritis. However, the role of IL-10 during endochondral bone formation and its mechanism of action have not been elucidated. Methods: IL-10-/- mice and IL-10-treated tibial organ cultures were used to study loss and gain of IL-10 functions, respectively, during endochondral bone formation. Primary chondrocytes from the long bones of mouse embryos were cultured with and without IL-10. To assess the role of IL-10 in chondrogenic differentiation, we conducted mesenchymal cell micromass cultures. Results: The lengths of whole skeletons from IL-10-/- mice were similar to those of their wild-type littermates, although their skull diameters were smaller. The tibial growth plates of IL-10-/- mice showed shortening of the proliferating zone. Treatment with IL-10 significantly increased tibial lengths in organ culture. IL-10 also induced chondrocyte proliferation and hypertrophic differentiation in primary chondrocytes in vitro. Mechanistically, IL-10 activated STAT-3 and the Smad1/5/8 and ERK-1/2 MAP kinase pathways and induced the expression of bone morphogenetic protein 2 (BMP-2) and BMP-6 in primary chondrocytes. Furthermore, the blocking of BMP signaling attenuated the IL-10-mediated induction of cyclin D1 and RUNX-2 in primary chondrocytes and suppressed Alcian blue and alkaline phosphatase staining in mesenchymal cell micromass cultures. Conclusion: These results indicate that IL-10 acts as a stimulator of chondrocyte proliferation and chondrogenic or hypertrophic differentiation via activation of the BMP signaling pathway. © 2013, American College of Rheumatology

A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma

BACKGROUND: The aim of this study was to examine the efficacy and safety of everolimus in patients with progressive unresectable adenoid cystic carcinoma (ACC). METHODS: Histologically confirmed ACC patients with documented disease progression within 12 months prior to the study entry were eligible. Everolimus was given at a dose of 10 mg daily until progression or occurrence of unacceptable toxicities. The primary endpoint was a 4-month progression-free survival (PFS). RESULTS: A total of 34 patients were enrolled. The 4-month PFS probability was 65.5% (95% one-sided confidence interval [CI], 47.7 to infinity). Median PFS duration was 11.2 months (95% CI, 3.6 to 15.8). Complete or partial response was not achieved. Twenty-seven (79.4%, 95% CI, 63.2 to 89.6) patients showed stable disease (SD). Tumor shrinkage within SD criteria was observed in 15 patients (44.1%) and SD lasting 6 months was observed in 13 patients (38.2%). Four patients had disease progression. Among the 18 patients with both pre- and post-treatment (at 8 weeks) FDG-PET scans available, 8 patients (44.4%) showed a partial metabolic response, defined as a ≥25% reduction in maximum standardized uptake values (SUVmax). The most common adverse events were stomatitis, anemia, asthenia, and leukopenia. No unexpected everolimus related toxicities were reported. CONCLUSIONS: Everolimus showed promising efficacy and good tolerability in progressive unresectable ACC. TRIAL REGISTRATION: ClinicalTrials.gov identifier, NCT0115284

Potential redox-sensitive Akt activation by dopamine activates Bad and promotes cell death in melanocytes

Dopamine (DA) is a well known oxidative neurotoxin. In addition, Akt has been reported to deliver a survival signal that inhibits apoptosis. However, it has also been reported that chronic Akt activation leads to apoptosis in response to oxidative stress. The objective of the present study was to investigate the possible role of the Akt pathway in vitiligo and its possible relationship with DA-induced cell death using Mel-Ab cells. Cultured Mel-Ab cells were treated with DA with and without N-Acetyl-L-cysteine (NAC), which is known to have antioxidative properties. Cell viability was then assessed by a crystal violet assay and Annexin staining was performed. The changes in the expression of Akt were analyzed by western blot analysis. The cell viability was reduced by approximately 60% in response to treatment with 500 µM DA, and NAC effectively prevented this cytotoxic effect. Likewise, treatment with DA produced numerous Annexin positive cells, while treatment with NAC prevented this apoptotic cell death. Akt was slowly phosphorylated after treatment with DA, while NAC clearly inhibited the DA-induced Akt activation. Western blot analysis also showed that treatment with DA induced the activation of Bad. Finally, LY294002 exerted a protective effect against DA-induced apoptotic cell death. DA may induce redox-sensitive Akt activation and increase the level of Bad, which can promote cell death by heterodimerization with survival proteins. Moreover, NAC effectively protects against DA-induced melanocyte death via inhibition of DA-induced Akt activation

Bacteriology division, Animal and Plant Quarantine Agency

ABSTRACT Background: Haemophilus parasuis is the etiological agent responsible for causing Glässer's disease in pigs, which are major respiratory pathogens that cause large economic losses in the pig industry worldwide. H. parasuis obtains transferrinbound iron by expressing two surface receptors, transferrin-binding protein A and B (TbpA and B). The TbpA and B are capable of binding to transferrin, and an impairment of iron uptake mechanisms is likely to induce virulence. For this reason, these proteins can be useful as a candidate target for H. parasuis vaccination. Also, the live attenuated Salmonella Typhimurium expressing recombinant antigens from other pathogens are attractive vaccine vectors. Materials, Methods & Results: In this study, we constructed attenuated S. Typhimurium vaccine strain by porcine neurtophil passage method. By the passage, the ability of the neutrophil-adapted isolate to utilize d-xylose was lost, while the ability of the strain to ferment trehalose was delayed after 2 or more days of the culture. The aspartate β-semialdehyde dehydrogenase (asd) gene was eliminated from S. Typhimurium by one-step PCR. Deletion of asd region was confirmed by PCR using primers specific to the endpoints of the targeted region. TbpA fragment was amplified by PCR from genomic DNA of H. parasuis serotype 5. To construct TbpA expression plasmids, tbpA was subcloned downstream from the β-lactamase signal sequence in the multicopy asd + pYA3493 vector. This plasmid was subsequently electrotransformed into attenuated S. Typhimurium. The 636bp fragment of the tbpA gene of H. parasuis in attenuated S. Typhimurium was amplified by PCR and the in-frame fusion of the tbpA was confirmed by nucleotide sequencing. The used this strain with Asd + balanced-lethal plasmid pYA3493 vector to specify recombinant TbpA antigen, conserved immunogenic region of H. parasuis. Expression of the TbpA protein was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Western blot. The size of TbpA protein was estimated at about 30kDa. Mice were administered orally in order to evaluate protective efficacy of this vaccine strain against H. parasuis serotype 5. For efficacy test, female ICR mice (5 weeks old) were orally injected, intraperitoneally challenged with a lethal dose (4X10 5 CFU/mouse) of H. parasuis serotype 5, and examined the survival rates compared with vaccination and non-vaccination group. The experiment was terminated two weeks post-challenge. The live attenuated S. Typhimurium conserved pYA3493-TbpA antigen vaccine protected 40% of immunized mice against challenge of H. parasuis serotype 5. This result suggested that the live attenuated Salmonella Typhimurium vaccine expressing TbpA might be protection for Glässer's disease outbreaks caused by H. parasuis. Discussion: This paper has shown protected mice that attenuated S. Typhimurium strain using pYA3493 expresses TbpA antigen against H. parasuis. Vaccination using bacterins is an efficient way to control outbreaks of Glässers disease, but significant variability has been reported. Therefore, the development of a new vaccine system to prevent Glässers disease using pYA3493-TbpA will avoid the disadvantages of the currently used vaccines. We need further works to enhance protection rate and to determine the potential of the vaccine in pigs

Allelic and Haplotypic Diversity of HLA-A, -B, -C, and-DRB1 Genes in Koreans Defined by High-resolution DNA Typing

배경 : HLA 형별은 혈청학적 수준(generic level)에서도 다형성이 심하지만 대립유전자 수준에서는 더욱 심한 다형성을 보이고 인종 간에 큰 차이를 나타내는 것으로 알려졌다. 본 연구에서는 고해상도 DNA 검사법을 이용하여 한국인에서 HLA대립유전자 형별과 일배체형의 종류 및 빈도를 알아보고자 하였다. 방법 : 건강한 한국인 474명을 대상으로 HLA-A, -B, -C, -DRB1 유전자에 대해 두 단계의 검사로 대립유전자(4자리수) 형별 분석을 실시하였다. 1단계로 혈청학적 수준의 형별검사를 혈청학적 검사법이나 sequence-specific oligonucleotide(PCR-SSO) 방법으로 시행하였고, 그 다음 단계로 대립유전자 형별검사를 class I은 exon 2와 exon3, DRB1은 exon 2에 대해 single-strand conformation polymorphism (PCR-SSCP) 또는 직접염기서열분석법을 이용하여 실시하였다. HLA 대립 유전자의 유전자 빈도, 일배체형 빈도, 연쇄불평형 값은 maximum likelihood 원리에 근거한 제11차 국제조직적합성워크숍 컴퓨터 프로그램을 이용하여 산출하였다. 결과 : 한국인에서 검출된 HLA-A, -B, -C, DRB1 대립유전자 형별은 각각 21, 40, 22, 29종이었다. 이 중에 유전자 빈도 10% 이상을 보인 대립유전자 형별(빈도순 나열)은 A*02:01, A*24:02, A*33:03; B*51:01; C*01:02, C*03:03; RB1*09:01등이었다. HLA 일배체형의 분석 결과 0.5% 이상의 빈도를 나타내는 2-유전자좌 일배체형은 A-C 44종, B-C 42종, A-B 51종, B-DRB1 52종이었고, 3-유전자좌 일배체형은 A-C-B 42종, A-B-DRB1 34종이었다. 한국인에서 빈도 1% 이상의 A-B-DR 일배체형은 13종으로, 전체 일배체형의 26.0%를 차지하였고, 2% 이상으로 가장 흔한 A-B-DR 일배체형은 A*33:03-B*44:03-DRB1*13:02 (3.7%), A*33:03-B*44:03-DRB1*07:01 (3.0%), A*33:03-B*58:01-DRB1*13:02 (3.0%), A*24:02-B*07:02-DRB1*01:01 (2.8%), A*30:01-B*13:02-DRB1* 07:01 (2.3%), A*11:01-B*15:01-DRB1*04:06 (2.2%) 등 6종이었다. 결론 : 본 연구를 통해 한국인의 대립유전자 수준의 HLA 형별과 HLA 일배체형 빈도에 대한 자료를 제시하였으며, 본 연구의 결과는 한국인에서 장기이식, 질환연관성 연구, 인류유전학적 연구 등에서 중요한 기초자료로 이용될 수 있을 것으로 기대된다. Background : In this study, we used high-resolution DNA typing to investigate the distribution of HLA alleles and haplotypes in Koreans. Methods : HLA-A, -B, -C, and -DRB1 alleles were genotyped at the allelic (4-digit) level in 474 healthy Koreans. HLA genotyping was performed in two steps. Initially, serologic typing or generic-level DNA typing was performed using the FOR-sequence-specific oligonucleotide method, and then allelic DNA typing (exons 2 and 3 for class I, and exon 2 for DRB1) was carried out using the FOR-single-strand conformation polymorphism method or sequence-based typing. HLA allele and haplotype frequencies and linkage disequilibrium values were calculated by the maximum likelihood method using a computer program developed for the 11th International Histocompatibility Workshop. Results : A total of 21 HLA-A, 40 HLA-B, 22 HLA-C, and 29 HLA-DRB1 alleles were found in Koreans. The most frequent alleles in each locus with frequencies of >= 10% were, in decreasing order of frequency, as follows: A star 24:02, A star 02:01, A(star)33:03; B(star)51:01; C(star)01:02, C(star)03:03; and DRB1(star)09:01. The numbers of two- and three-locus haplotypes with frequencies of >0.5% were as follows: 44 A-C, 42 B-C, 51 A-B, 52 B-DRB1, 42 A-C-B, and 34 A-B-DRB1. Thirteen A-B-DRB1 haplotypes with frequencies of >= 1.0% comprised 26.0% of the total haplotypes. The six most common haplotypes were as follows: A(star)33:03-B(star)44:03-DRB1(star)3:02 (3.7%), A(star)33:03-B(star)44:03-DRB1(star)07:01 (3.0%), A(star)33:03-B(star)58: 01-DRB1(star)13:02 (3.0%), A(star)24:02-B(star)07:02-DRB1(star)01:01 (2.8%), A(star)30:01-B(star)13:02-DRB1(star)07:01 (2.3%), and A(star)11:01-B(star)15:01-DR81(star)04:06 (2.2%). Conclusions : The information obtained in this study can be used as basic data for Koreans in the fields of organ transplantation, disease association, and anthropologic studies. (Korean J Lab Med 2010;30:685-96)Yoon JH, 2010, TISSUE ANTIGENS, V75, P170, DOI 10.1111/j.1399-0039.2009.01418.xLee KW, 2009, HUM IMMUNOL, V70, P464, DOI 10.1016/j.humimm.2009.03.010Yang KL, 2009, HUM IMMUNOL, V70, P269, DOI 10.1016/j.humimm.2009.01.015YI DY, 2009, KOREAN J LAB MED, V29, pS425Whang DH, 2008, KOREAN J LAB MED, V28, P465, DOI 10.3343/kjlm.2008.28.6.465Trachtenberg E, 2007, TISSUE ANTIGENS, V70, P455, DOI 10.1111/j.1399-0039.2007.00932.xCano P, 2007, HUM IMMUNOL, V68, P392, DOI 10.1016/j.humimm.2007.01.014Yang G, 2006, TISSUE ANTIGENS, V67, P146, DOI 10.1111/j.1399-0039.2005.00529.xMACK SJ, 2006, IMMUNOBIOLOGY HUMAN, V1, P291Itoh Y, 2005, IMMUNOGENETICS, V57, P717, DOI 10.1007/s00251-005-0048-3Lee KW, 2005, TISSUE ANTIGENS, V65, P437, DOI 10.1111/j.1399-0039.2005.00386.xOttinger HD, 2004, TRANSPLANTATION, V78, P1077, DOI 10.1097/01.TP.0000137791.28140.93Flomenberg N, 2004, BLOOD, V104, P1923, DOI 10.1182/blood-2004-03-0803Song EY, 2004, HUM IMMUNOL, V65, P270, DOI 10.1016/j.humimm.2003.12.005HWANG SH, 2004, KOREAN J LAB MED, V24, P396ROH EY, 2003, KOREAN J LAB MED, V23, P420WHANG DH, 2003, KOREAN J LAB MED, V23, P52Lee KW, 2010, KOREAN J LAB MED, V30, P203, DOI 10.3343/kjlm.2010.30.3.203Morishima Y, 2002, BLOOD, V99, P4200Song EY, 2002, TISSUE ANTIGENS, V59, P475Song EY, 2001, HUM IMMUNOL, V62, P1142NAKAJIMA F, 2001, MHC, V8, P1Saito S, 2000, TISSUE ANTIGENS, V56, P522Park MH, 2000, TISSUE ANTIGENS, V55, P250DUNN P, 2000, IHWG TECHNICAL MANUA, P1Park MH, 1999, TISSUE ANTIGENS, V53, P386Marsh SGE, 2010, TISSUE ANTIGENS, V75, P291Petersdorf EW, 1998, BLOOD, V92, P3515Park MH, 1998, TISSUE ANTIGENS, V51, P347Wang H, 1997, TISSUE ANTIGENS, V50, P620Cereb N, 1997, TISSUE ANTIGENS, V50, P74Bannai M, 1997, TISSUE ANTIGENS, V49, P376Bannai M, 1996, HUM IMMUNOL, V46, P107CEREB N, 1995, TISSUE ANTIGENS, V45, P1BANNAI M, 1994, EUR J IMMUNOGENET, V21, P1IMANISHI T, 1992, HLA 1991, V1, P76TOKUNAGA K, 1992, EVOLUTION DISPERSAL, P599